When considered against active comparators, semaglutide also increased the likelihood of participants losing 5% fasting body weight, with ORs ranging from 1.29 (95% CI 0.70, 2.13 [T2DM]) to 2.17 (95% CI 1.44, 3.27 [NGT]) with liraglutide 3.0 mg and from 6.09 (95% CI 2.86, 11.95 [total population]) to 7.75 (95% CI 5.29, 11.37 [non-T2DM]) with orlistat 120 mg three times daily (TID)
They are not sold for clinical, therapeutic, or personal use.
About SELECT clinical study SELECT (Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity) is a randomised, double-blind, parallel-group, placebo-controlled trial designed to evaluate the efficacy of semaglutide 2.4 mg versus placebo as an adjunct to standard of care for the prevention of major adverse cardiac events (MACE) in people with overweight or obesity and established cardiovascular disease with no prior history of diabetes
It's about starting a journey without asking for permission from a system that wasn't designed with your specific goals in mind
Factors like age, skin type, genetics, and how much weight was lost all play a role
Eating Enough Nutrients When Appetite Is Suppressed When appetite plummets, the biggest challenge is getting enough protein, vitamins, and minerals despite low hunger signals
.png)
